Resilient Biopharma Leadership With Ambrx's Dan O'Connor
Business Of Biotech
00:00
N-4-2: A New Approach to Breast Cancer Treatment
The antibody does not or the agency does not fall apart and bloodstream. It gets the cancer cell and delivers the toxic payment. For 70 days, that program's been going on for many years. In fact, it was licensed to a partner in China, who just announced successful facial results with it in metastatic breast cancer. And then instead, look to license the program so that we could focus our resources on an earlier program targeting prostate cancer using the same technology I just described. The company had been developing the same program in a very, very large of a large-face resubedy.
Transcript
Play full episode
